Results: The cohort had the following distribution of LAMS scores: LAMS 0-15%; LAMS 1-5%, LAMS 2-12%, LAMS 3-20%; LAMS 4-18%; LAMS 5-30%. A total of 62% had a LAMS score of 3 or less, while 38% had a score of 4 or 5. A LAMS of 4 or 5 was significantly associated with having advanced neuroimaging such as CT perfusion ¼(P¼0.0003) having mechanical thrombectomy (MT) ¼(P¼0.0054) getting thrombolysis (tPA) ¼(P¼0.0026) having a higher NIHSS at hospital arrival (P<0.0001) and hospital discharge (P¼0.0175)
Study Objectives: As new classes of anticoagulants become more popular, more patients taking these medications are presenting after minor head injuries. Patients requiring anticoagulation may take warfarin, novel oral anticoagulants (NOACs like Factor Xa inhibitors), antiplatelet agents, heparins, or a combination of these classes. It is unclear if certain classes of anticoagulants are more or less likely to cause intracranial hemorrhage (ICH) after minor head injury compared to the others. We sought to determine if any of the classes were more likely to cause ICH than the others.
Methods: A retrospective cohort study was conducted of consecutive patients on an anticoagulant with minor head injury presenting to emergency department (ED) of a suburban, academic, Level 1 Trauma Center. Patients were excluded if they were on aspirin only or if they were on more than one class of anticoagulant. Patients were grouped by the class of anticoagulant: warfarin, NOACs, anti-platelets, and heparin (including low-molecular weight heparin). All patients had a non-contrast CT scan of their heads in the ED. Charts were reviewed to determine if an ICH was present. ICH rates with 95% confidence intervals (CI) were calculated and a one-way ANOVA with significance set at p<0.05 was conducted to compare the likelihood of ICH for the different classes of anticoagulants.
Results: A total of 919 patients on an anticoagulant (other than aspirin alone) presented with an isolated head injury. 19 were excluded for being on multiple anticoagulants. Of the remaining 900, 536 were on warfarin, 262 were on NOACs, 62 were on antiplatelets, and 40 were on heparin. The average age of the included patients was 78.1 years and 50.3% were male. The groups were similar with respect to age and sex. The rate of ICH in the warfarin class was 7.8% (CI: 5.6, 10.1), in the NOAC class was 6.9% (CI: 3.8, 9.9), in the antiplatelet class was 14.5% (CI: 5.7, 23.3), and in the heparin class was 14.6% (CI: 3.7, 25.6). There was no significant difference of anticoagulant class on likelihood of ICH [F (3, 897 Study Objectives: To determine changes in serum glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) concentrations up to 24 hours post-study enrollment. Study results will augment current available data and help elucidate 1) the importance of time post-injury testing and 2) the potential usefulness of serial testing to diagnose and follow clinical progression of patients with TBI.
Methods: This prospective multi-center observational study included adult headinjured subjects with a Glasgow Coma Scale score 13-15 for whom an emergency head CT was obtained and uninjured controls. Enrollment was stratified by head CT negative (CT-) or CT positive (CT+) findings for traumatic intracranial pathology. Serum samples were obtained at study baseline (within 6 hours of injury) and every 4 hours for up to 24 hours (controls at baseline and 4 hours only) and were analyzed using the recently FDA approved biomarker (Banyan BTI TM ) test for GFAP and UCH-L1. Kruskal-Wallace (adjustment for pairwise-comparisons) was used to compare values between the 3 groups. Median differences in GFAP and UCH-L1 from baseline and samples obtained at later study times between CT+ and CT-patients were analyzed (Wilcoxon rank sum test) and differences within subjects across time were evaluated (signed rank test).
Results: 192 subjects were enrolled into 3 study groups; 78 were CT+ (73.1% male), 74 CT-(60.8% male), and 40 controls (50% male). There was a significant difference in both biomarker values at baseline among the 3 groups (p<0.001 for both and all pairwise comparisons were significant). For controls, the baseline median (25 th , 75 th ) GFAP level for was 17 (10.5, 32) and remained low at time 4 hours (18 [7, 29] resulting in a median difference of 0; p¼0.57) and for UCH-L1 were 102 (81, 135) and 88 (68, 133) respectively (median difference -1.0; p¼0.57). The table shows the same baseline values and the changes from baseline to selected time points. GFAP levels tended to remain elevated and increase among all injured patients but the increase in median GFAP level at 24 hours was greater in CT+ patients than CT-patients (p¼0.03). Median UCH-L1 decreased over the same time period but at 24 hours the decrease did not differ between CT+ and CT-patients (p¼0.07).
Conclusions: Head-injured subjects had higher baseline serum GFAP and UCH-L1 concentrations that control subjects and injured patients who were CT+ had higher initial GFAP and UCH-L1 serum concentrations than CT-patients. GFAP rose during the 24 hour period and the rise was greater among CT+ patients. In contrast, UCH-L1 decreased but the decrease did not differ between CT+ and CT-patients.
Although not yet in clinical practice, these FDA approved biomarkers have potentially attractive properties for evaluating patients at both early and later times to ED care and for following the clinical course of patients with TBI.
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